Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

ABSTRACT: Despite improvements in early detection and advances in treatment, patients with prostate cancer continue to die from their disease. Minimal residual disease after primary definitive treatment can lead to relapse and distant metastases, and increasing evidence suggests that circulating tumour cells (CTCs) and bone marrow-derived disseminated tumour cells (BM-DTCs) can offer clinically relevant biological insights into prostate cancer dissemination and metastasis. Using epithelial markers to accurately detect CTCs and BM-DTCs is associated with difficulties, and prostate-specific markers are needed for the detection of these cells using rare cell assays. Putative prostate-specific markers have been identified, and an optimized strategy for staining rare cancer cells from liquid biopsies usi

SUBMITTER: van der Toom EE 

PROVIDER: S-EPMC6324967 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature